Impact of different postoperative adjuvant therapies on the survival of early-stage cervical cancer patients with one intermediate-risk factor: A multicenter study of 14 years
机构:[1]Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, China[2]Department of Midwifery, Faculty of Health, Dongguan Polytechnic, Dongguan, China[3]Department of Gynecology, Fourth Hospital, Hebei Medical University, Shijiazhuang, China临床科室妇科河北医科大学第四医院[4]Department of Obstetrics and Gynecology, Affiliated Jiangmen Hospital of SUN YATSEN University, Jiangmen, China[5]Department of Gynecology, The First Hospital of China Medical University, Shenyang, China[6]Department of Obstetrics and Gynecology, Pan Yu Central Hospital, Guangzhou, China[7]Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China
Objective: To compare survival outcomes of different postoperative adjuvant therapies (PATs) for early-stage cervical cancer (ECC) patients with one intermediate-risk pathological factor (IPF).Methods: A total of 2889 patients with stage IA1 to IIA2 cervical cancer were included in this study. Three PAT groups were identified, namely a no adjuvant therapy (NAT) group (n = 773), an adjuvant radiotherapy/chemoradiotherapy (ART) group (n = 1648) and an adjuvant chemotherapy (ACT) group (n = 468). Kaplan-Meier analysis and COX regression analysis were used to compare the overall survival (OS) and disease-free survival (DFS) among the three groups, before and after propensity score matching (PSM).Results: The recurrence and mortality rate rates in the NAT, ART and ACT groups were 9.2%, 8.6%, and 7.9%, respectively (p = 0.737). Kaplan-Meier analysis demonstrated no significant differences in the NAT, ART, and ACT groups in 5-year OS rates (92.8% vs. 93.6% vs. 94.7%, p = 0.594) and DFS rates (88.7% vs. 89.6% vs. 90.5%, p = 0.772). Post-hoc tests yielded similar results, with no differences in 5-year OS and DFS (NAT vs. ART, before and after matching, p > 0.05); (NAT vs. ACT, before and after matching, p > 0.05); and (ACT vs. ART, before and after matching, p > 0.05).Conclusion: Postoperative adjuvant radiotherapy, chemoradiotherapy, and chemotherapy are not associated with survival outcomes of ECC patients with one IPF. Considering the side effects and impact on patients' quality of life, the PATs should be carefully considered.
基金:
National Science and Technology Support Program of China [2014BAI05B03]; National Natural Science Fund of Guangdong [2015A030311024]; Dongguan Sci-tech Commissioner Program [20221800500661]; Science and Technology Plan of Guangzhou [158100075]
第一作者机构:[1]Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, China[2]Department of Midwifery, Faculty of Health, Dongguan Polytechnic, Dongguan, China
共同第一作者:
通讯作者:
通讯机构:[2]Department of Midwifery, Faculty of Health, Dongguan Polytechnic, Dongguan, China[*1]Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, No. 1838, Guangzhou Avenue, Guangzhou 510515, China.
推荐引用方式(GB/T 7714):
Ye Yanna,Li Zhiqiang,Kang Shan,et al.Impact of different postoperative adjuvant therapies on the survival of early-stage cervical cancer patients with one intermediate-risk factor: A multicenter study of 14 years[J].JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH.2023,49(6):1579-1591.doi:10.1111/jog.15632.
APA:
Ye, Yanna,Li, Zhiqiang,Kang, Shan,Zhan, Xuemei,Zhang, Yi...&Chen, Chunlin.(2023).Impact of different postoperative adjuvant therapies on the survival of early-stage cervical cancer patients with one intermediate-risk factor: A multicenter study of 14 years.JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH,49,(6)
MLA:
Ye, Yanna,et al."Impact of different postoperative adjuvant therapies on the survival of early-stage cervical cancer patients with one intermediate-risk factor: A multicenter study of 14 years".JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH 49..6(2023):1579-1591